Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 112, Issue 2, Pages 421-423Publisher
BLACKWELL SCIENCE LTD
DOI: 10.1046/j.1365-2141.2001.02599.x
Keywords
allogeneic stem cell transplantation; donor lymphocyte infusion; graft-vs.-host disease; multiple myeloma
Categories
Ask authors/readers for more resources
Two patients with persistent disease after allografting for multiple myeloma received donor T-cell lymphocyte infusion (DLI) (1.5 x 10(8) and 7 x 10(7)) to induce a graft-vs.-myeloma effect for further tumour regression after withdrawal of immunosuppression. The interval between stem cell transplantation and DLI was 8 and 14 months respectively. Both patients converted from partial to complete remission, lasting 12+ and 28+ months. Immunofixation became negative after 3 and 4 months. The main toxicity was grade II and III acute graft-vs.-host disease (GvHD) and limited or extensive chronic GvHD in each patient. We conclude that DLI induced further tumour reduction in patients with persistent disease after allografting for multiple myeloma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available